Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, 8025, Grand Ave, West Des Moines, IA, 50266, USA.
Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
Med Oncol. 2024 Jan 29;41(3):67. doi: 10.1007/s12032-023-02281-6.
Ovarian cancer is a prominent cancer worldwide with a relatively low survival rate for women diagnosed. Many individuals are diagnosed in the late stage of the disease and are prescribed a wide variety of treatment options. Current treatment options are primarily a combination of surgery and chemotherapy as well as a new but promising treatment involving immunotherapy. Nevertheless, contemporary therapeutic modalities exhibit a discernible lag in advancement when compared with the strides achieved in recent years in the context of other malignancies. Moreover, many surgery and chemotherapy options have a high risk for recurrence due to the late-stage diagnosis. Therefore, there is a necessity to further treatment options. There have been many new advancements in the field of immunotherapy. Immunotherapy has been approved for 16 various types of cancers and has shown significant treatment potential in many other cancers as well. Researchers have also found many promising outlooks for immunotherapy as a treatment for ovarian cancer. This review summarizes many of the new advancements in immunotherapy treatment options and could potentially offer valuable insights to gynecologists aimed at enhancing the efficacy of their treatment approaches for patients diagnosed with ovarian cancer.
卵巢癌是一种全球范围内显著的癌症,女性患者的生存率相对较低。许多患者在疾病晚期被诊断出来,并被开处了各种各样的治疗方案。目前的治疗方案主要是手术和化疗的结合,以及一种新的但有前途的免疫疗法。然而,与近年来在其他恶性肿瘤方面取得的进展相比,当代治疗方法的进展明显滞后。此外,由于晚期诊断,许多手术和化疗方案的复发风险很高。因此,有必要进一步探索治疗方案。免疫疗法领域有许多新的进展。免疫疗法已经批准用于 16 种不同类型的癌症,并在许多其他癌症中显示出显著的治疗潜力。研究人员还发现了免疫疗法作为卵巢癌治疗方法的许多有前景的展望。这篇综述总结了免疫疗法治疗方案的许多新进展,可能为妇科医生提供有价值的见解,旨在提高他们对卵巢癌患者治疗方法的疗效。
Gynecol Oncol. 2015-5
Mol Pharm. 2024-2-5
Med Oncol. 2022-9-29
Curr Treat Options Oncol. 2016-3
Arch Immunol Ther Exp (Warsz). 2022-8-9
Expert Opin Biol Ther. 2014-1
Biomedicines. 2025-6-22
J Transl Med. 2025-6-3
J Hematol Oncol. 2022-3-18
Br J Radiol. 2021-9-1
Anticancer Res. 2021-7
Int J Mol Sci. 2021-6-18
Curr Opin Chem Biol. 2021-6
Front Immunol. 2020
J Ovarian Res. 2021-1-11